Abivax CEO Downplays Sale Talk, Eyes Capital Raise As Key Trial Data Readout NearsBenzinga • 03/24/26
Abivax in no rush for a deal, confident key June trial data can secure better terms for partnerships, CEO tells CNBCCNBC • 03/24/26
Abivax: Maintaining 'Strong Buy' On Buyout Speculation And Obefazimod AdvancementSeeking Alpha • 03/16/26
Billionaire Steve Cohen Owns Shares of This Stock That Has Soared 1,600% in The Past YearThe Motley Fool • 03/10/26
Abivax Presents First Evidence of Anti-Fibrotic Activity for Obefazimod Alongside New Clinical Efficacy and Safety Analyses in Inflammatory Bowel Disease at ECCO 2026GlobeNewsWire • 02/21/26
Missed Out on Eli Lilly? 2 Healthcare Stocks With Big Catalysts on the Horizon.The Motley Fool • 02/11/26
A little-known biotech stock has become a prime takeover target after surging nearly 1,700% last yearCNBC • 01/09/26